GUTS (Fractyl Health Inc.) רווח למניה בארבעת הרבעונים האחרונים

This chart confirms the market price reflects EPS (TTM) dynamics at 78.80. Fractyl Health, Inc. (GUTS) integrates gene therapy with endoscopic methods to combat diabetes. The company is developing partnerships with endocrinologists to improve treatment precision. The current strategic trajectory focuses on the commercial launch of innovations and securing US regulatory approvals for obesity therapy.
GUTS (Fractyl Health, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The combination of medical device development and gene therapy at Fractyl Health, Inc. (GUTS) mitigates regulatory risks, which directly impacts profit dynamics. By analyzing the annual change in net income per share over a rolling period on GURU.Markets, an investor assesses the growth rates of real earnings per share, determining the business's ability to generate value amid the Federal Reserve's tight monetary policy.